VAG
ABBV icon

VisionPoint Advisory Group’s AbbVie ABBV Stock Holding History

VisionPoint Advisory Group’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Buy
3,997
+436
+12% +$93.8K 0.16% 143
2026
Q1 		$774K Sell
3,561
-69
-2% -$15.3K 0.15% 161
2025
Q4 		$829K Buy
3,630
+44
+1% +$10K 0.16% 144
2025
Q3 		$830K Sell
3,586
-93
-3% -$18.9K 0.17% 141
2025
Q2 		$683K Buy
3,679
+1,556
+73% +$289K 0.15% 152
2025
Q1 		$445K Buy
2,123
+473
+29% +$92K 0.15% 121
2024
Q4 		$296K Sell
1,650
-271
-14% -$49.8K 0.1% 144
2024
Q3 		$379K Sell
1,921
-546
-22% -$102K 0.13% 124
2024
Q2 		$423K Sell
2,467
-4,480
-64% -$742K 0.15% 115
2024
Q1 		$1.27M Sell
6,947
-3,311
-32% -$571K 0.46% 62
2023
Q4 		$1.59M Buy
10,258
+634
+7% +$92.4K 0.59% 50
2023
Q3 		$1.43M Buy
9,624
+201
+2% +$29.5K 0.62% 49
2023
Q2 		$1.27M Sell
9,423
-857
-8% -$126K 0.52% 56
2023
Q1 		$1.51M Sell
10,280
-3,455
-25% -$528K 0.67% 41
2022
Q4 		$2.11M Buy
13,735
+6,005
+78% +$921K 0.87% 31
2022
Q3 		$1.04M Buy
7,730
+199
+3% +$28.6K 0.5% 29
2022
Q2 		$1.07M Sell
7,531
-1,237
-14% -$189K 0.42% 39
2022
Q1 		$1.35M Buy
+8,768
New +$1.27M 0.63% 38
2021
Q1 		– Sell
-2,038
Closed -$218K – 114
2020
Q4 		$218K Sell
2,038
-5,432
-73% -$522K 0.11% 130
2020
Q3 		$654K Sell
7,470
-3,229
-30% -$304K 0.28% 49
2020
Q2 		$1.04M Buy
10,699
+7,544
+239% +$664K 0.42% 34
2020
Q1 		$240K Sell
3,155
-450
-12% -$38.3K 0.11% 96
2019
Q4 		$319K Sell
3,605
-1,026
-22% -$85.2K 0.13% 82
2019
Q3 		$346K Buy
4,631
+1,133
+32% +$77.7K 0.09% 86
2019
Q2 		$254K Buy
3,498
+40
+1% +$3.14K 0.07% 110
2019
Q1 		$279K Buy
+3,458
New +$283K 0.08% 105

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

VisionPoint Advisory Group's ABBV Position: Q2 2026 in Review

VisionPoint Advisory Group increased its AbbVie (ABBV) stake by 12% in Q2 2026, buying an estimated $93.8K and bringing the position to 3,997 shares worth $1.01M. The position accounts for 0.16% of the portfolio, ranked #143.

VisionPoint Advisory Group first reported a position in ABBV in Q1 2019 and has held it in 26 quarters since. The position peaked at $2.11M in Q4 2022. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • VisionPoint Advisory Group held 3,997 shares of AbbVie worth $1.01M as of Q2 2026.
  • VisionPoint Advisory Group bought 436 AbbVie shares in Q2 2026, an estimated $93.8K.
  • AbbVie made up 0.16% of VisionPoint Advisory Group's portfolio in Q2 2026, its #143 holding.
  • VisionPoint Advisory Group first reported a position in AbbVie in Q1 2019 and has held it in 26 quarters since.
  • VisionPoint Advisory Group's AbbVie position peaked at $2.11M in Q4 2022.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on VisionPoint Advisory Group's 13F filing for Q2 2026, filed 7 Jul 2026.